Skip to main content
. 2019 Aug 6;18(4):3887–3895. doi: 10.3892/ol.2019.10715

Figure 3.

Figure 3.

mPFS of patients treated with first-line and second-line TKIs. (A) The mPFS times of patients treated with first and second-line TKIs were 10.5 and 13.0 months (P=0.965), respectively. (B) In patients with the 19-del mutation, the mPFS times of patients treated with first- and second-line TKIs were 11.3 and 11.0 months (P=0.140), respectively. (C) In patients with the 21-L858R mutation, the mPFS times of those treated with first- and second-line TKIs were 8.8 and 13.6 months (P=0.03), respectively. mPFS, median progression-free survival; TKIs, tyrosine kinase inhibitors.